Table 2:
Characteristics of Breast Cancer Patients Diagnosed 2007–2013, According to History of Mental Illness
| Covariate | Level | History of Mental Illness | p value* | |||
|---|---|---|---|---|---|---|
| No n=16,435 | Yes n=5,459 | |||||
| Age at Diagnosis | 68–74 | 7,006 | 42.6% | 2,302 | 42.2% | 0.004 |
| 75–84 | 7,307 | 44.5% | 2,352 | 43.1% | ||
| 85–94 | 2,057 | 12.5% | 774 | 14.2% | ||
| 95+ | 65 | 0.4% | 31 | 0.6% | ||
| Race | Asian | 808 | 4.9% | 142 | 2.6% | <0.001 |
| Black | 950 | 5.8% | 365 | 6.7% | ||
| Other | 108 | 0.7% | 41 | 0.8% | ||
| White | 14,569 | 88.6% | 4,911 | 90.0% | ||
| Ethnicity | Hispanic | 848 | 5.2% | 318 | 5.8% | 0.06 |
| Non-Hispanic | 15,587 | 94.8% | 5,141 | 94.2% | ||
| Year of Diagnosis | 2007 | 1,526 | 9.3% | 435 | 8.0% | <0.001 |
| 2008 | 2,280 | 13.9% | 687 | 12.6% | ||
| 2009 | 2,394 | 14.6% | 750 | 13.7% | ||
| 2010 | 2,360 | 14.4% | 771 | 14.1% | ||
| 2011 | 2,469 | 15.0% | 831 | 15.2% | ||
| 2012 | 2,572 | 15.6% | 920 | 16.9% | ||
| 2013 | 2,833 | 17.2% | 1,065 | 19.5% | ||
| Stage at Diagnosis | 1 | 10,081 | 61.3% | 3,113 | 57.0% | <0.001 |
| 2 | 4,790 | 29.1% | 1,744 | 31.9% | ||
| 3 | 1,075 | 6.5% | 441 | 8.1% | ||
| 4 | 160 | 1.0% | 41 | 0.8% | ||
| Unknown | 329 | 2.0% | 120 | 2.2% | ||
| Receptor Status | ER+PR+ | 14,151 | 86.1% | 4,638 | 85.0% | 0.04 |
| ER+PR− | 2,284 | 13.9% | 821 | 15.0% | ||
| Endocrine Therapy Class Used | AIs | 10,366 | 63.1% | 3,293 | 60.3% | <0.001 |
| Both | 1,468 | 8.9% | 435 | 8.0% | ||
| None | 3,155 | 19.2% | 1,227 | 22.5% | ||
| SERMs | 1,446 | 8.8% | 504 | 9.2% | ||
| Adjusted NCI Comorbidity Score | Mean (Median) | 1.8 (1.0) | 2.8 (2.0) | <.001 | ||
| Follow–Up Days | Mean (Median) | 1,141.7 (1,326.0) | 1,267.0 (1,150.0) | <.001 | ||
| Number Censored at Death | 889 | 5.4% | 487 | 8.9% | <.001 | |
| Number Who Initiated | 13,280 | 4,232 | ||||
| Days to Initiation | Mean (Median) | 157.7 (121.0) | 153.5 (115.0) | 0.002 | ||
| Number Who Discontinued | 3,376 | 1,127 | ||||
| aDays to Discontinuation | Mean (Median) | 727.0 (547.5) | 625.1 (445.0) | <.001 | ||
| Number With 1+ Years Endocrine Therapy Use | 11,120 | 3,397 | ||||
| bAverage Adherence (PDC) | Mean (Median) | 0.84 (0.90) | 0.84 (0.90) | 0.27 | ||
| Percent With 0.80 or Higher | 72.6 | 70.1 | 0.005 | |||
Proportion of Days Covered (PDC).
a
Discontinuation analyzed for the first 5 years of endocrine therapy use.
b
Average adherence calculated for patients with 1+ years of endocrine therapy use observed, and less than half of their follow-up spent hospitalized or in skilled nursing facilities.
*
Categorical and continuous p values calculated from Chi-square and Wilcoxon tests, respectively.